title: [The clinical significance of serum anti-p53 antibody as a monitoring marker in colorectal cancer].
abstract: We examined alterations in the level of serum anti-p53 antibody(S-p53 Ab) in colorectal cancer patients who underwent curative resection and analyzed the usefulness of S-p53 Ab as a monitoring marker for postoperative observation. The measurement of S-p53 Ab was performed preoperatively and postoperatively in 16 stage II/III colorectal cancer patients with a high level of S-p53 Ab. A time course analysis of both S-p53 Ab and CEA levels was performed in 6 of these patients who were carcinoembryonic antigen (CEA) positive. The median S-p53 Ab level was 29.9 U/mL and the half-life of the S-p53 Ab level was 40.3 days. In 4(25%) cases, the level of S-p53 Ab recovered to within normal limits by 79-142 days. When the half-lives of S-p53 Ab and CEA were analyzed in 6 patients who were both S-p53 Ab and CEA positive, the half-lives of S-p53 Ab and CEA were 32.3 and 13.2 days, respectively. In the case of recurrence with liver metastasis after resection of ascending colon cancer, the S-p53 Ab level did not respond quickly while the CEA level increased. Therefore, it is difficult to use the level of S-p53 Ab as a marker for monitoring treatment, and priority should be given to the examination of CEA and imaging modality.
authors.affiliation: Dept. of Digestive Tract and General Surgery, Saitama Medical University, Japan.
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Amano
authors.forename: Kensuke
authors.initials: K
authors.lastname: Kumamoto
authors.forename: Kouki
authors.initials: K
authors.lastname: Kuwabara
authors.forename: Toru
authors.initials: T
authors.lastname: Ishiguro
authors.forename: Tomonori
authors.initials: T
authors.lastname: Ohsawa
authors.forename: Norimichi
authors.initials: N
authors.lastname: Okada
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Kumagai
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Baba
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Ishibashi
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Tsuji
authors.forename: Norihiro
authors.initials: N
authors.lastname: Haga
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ishida
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000097:blood* / Q000276:immunology; D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood; D015179:Colorectal Neoplasms / Q000097:blood* / Q000276:immunology / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016159:Tumor Suppressor Protein p53 / Q000097:blood* / Q000276:immunology
chemical_list: D000906:Antibodies; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53